Iris Medicine is a cutting-edge brand that specializes in developing RNA-based therapies inspired by nature. Their small binding RNAs (sbRNAs) mimic natural RNAs, allowing them to modulate gene expression through highly selective binding events. The sbRNA platform enables a range of therapeutic approaches, including allele-selective inhibition and gene activation, making it a powerful tool in addressing serious diseases.

One area of focus for Iris Medicine is repeat expansion disorders, a group of devastating diseases that currently has over twenty known variants and continues to expand. Their technology leverages non-cooperative binding to WT transcripts and cooperative binding to expanded transcripts, selectively modulating RNA transcripts containing pathologic repeat sequences. This approach minimally impacts normal transcript expression, making it broadly applicable across diverse patient populations.

Iris Medicine is fueled by a deep sense of mission, driven by the belief that they can tackle human diseases with powerful science and a world-class team. Their leadership team, including Chairman and CEO Matt Patterson, Chief Scientific Officer Melissa Kotterman, and VP of Corporate Development Megan Blewett, brings extensive experience and expertise to the company. With a focus on pragmatic optimism, Iris Medicine is dedicated to making a positive impact on the lives of individuals living with life-altering conditions